250 related articles for article (PubMed ID: 33103454)
1. GPR40 deficiency is associated with hepatic FAT/CD36 upregulation, steatosis, inflammation, and cell injury in C57BL/6 mice.
Lu Z; Li Y; Syn WK; Li AJ; Ritter WS; Wank SA; Lopes-Virella MF; Huang Y
Am J Physiol Endocrinol Metab; 2021 Jan; 320(1):E30-E42. PubMed ID: 33103454
[TBL] [Abstract][Full Text] [Related]
2. Loss of GPR40 in LDL receptor-deficient mice exacerbates high-fat diet-induced hyperlipidemia and nonalcoholic steatohepatitis.
Lu Z; Li Y; Li AJ; Syn WK; Wank SA; Lopes-Virella MF; Huang Y
PLoS One; 2022; 17(11):e0277251. PubMed ID: 36331958
[TBL] [Abstract][Full Text] [Related]
3. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
[TBL] [Abstract][Full Text] [Related]
4. P2Y2R Deficiency Ameliorates Hepatic Steatosis by Reducing Lipogenesis and Enhancing Fatty Acid β-Oxidation through AMPK and PGC-1α Induction in High-Fat Diet-Fed Mice.
Dusabimana T; Park EJ; Je J; Jeong K; Yun SP; Kim HJ; Kim H; Park SW
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073834
[TBL] [Abstract][Full Text] [Related]
5. O-GlcNAcylation promotes the progression of nonalcoholic fatty liver disease by upregulating the expression and function of CD36.
Zhu H; Zhao T; Zhao S; Yang S; Jiang K; Li S; Kang Y; Yang Z; Shen J; Shen S; Tao H; Xuan J; Yang M; Xu B; Wang F; Jiang M
Metabolism; 2024 Jul; 156():155914. PubMed ID: 38642829
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte-Specific Disruption of CD36 Attenuates Fatty Liver and Improves Insulin Sensitivity in HFD-Fed Mice.
Wilson CG; Tran JL; Erion DM; Vera NB; Febbraio M; Weiss EJ
Endocrinology; 2016 Feb; 157(2):570-85. PubMed ID: 26650570
[TBL] [Abstract][Full Text] [Related]
7. Chemokine-like receptor 1 deficiency does not affect the development of insulin resistance and nonalcoholic fatty liver disease in mice.
Gruben N; Aparicio Vergara M; Kloosterhuis NJ; van der Molen H; Stoelwinder S; Youssef S; de Bruin A; Delsing DJ; Kuivenhoven JA; van de Sluis B; Hofker MH; Koonen DP
PLoS One; 2014; 9(4):e96345. PubMed ID: 24781986
[TBL] [Abstract][Full Text] [Related]
8. The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD).
Wang Z; Li S; Wang R; Guo L; Xu D; Zhang T; Xu Y; Wang W; Wang M; Gan Z; Wang X
Mol Med; 2020 Jun; 26(1):54. PubMed ID: 32503411
[TBL] [Abstract][Full Text] [Related]
9. Increased hepatic CD36 expression with age is associated with enhanced susceptibility to nonalcoholic fatty liver disease.
Sheedfar F; Sung MM; Aparicio-Vergara M; Kloosterhuis NJ; Miquilena-Colina ME; Vargas-Castrillón J; Febbraio M; Jacobs RL; de Bruin A; Vinciguerra M; García-Monzón C; Hofker MH; Dyck JR; Koonen DP
Aging (Albany NY); 2014 Apr; 6(4):281-95. PubMed ID: 24751397
[TBL] [Abstract][Full Text] [Related]
10. 1,2,3,4,6 penta-O-galloyl-β-D-glucose ameliorates high-fat diet-induced nonalcoholic fatty liver disease and maintains the expression of genes involved in lipid homeostasis in mice.
Kant R; Lu CK; Nguyen HM; Hsiao HH; Chen CJ; Hsiao HP; Lin KJ; Fang CC; Yen CH
Biomed Pharmacother; 2020 Sep; 129():110348. PubMed ID: 32554245
[TBL] [Abstract][Full Text] [Related]
11. Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans.
Cruces-Sande M; Vila-Bedmar R; Arcones AC; González-Rodríguez Á; Rada P; Gutiérrez-de-Juan V; Vargas-Castrillón J; Iruzubieta P; Sánchez-González C; Formentini L; Crespo J; García-Monzón C; Martínez-Chantar ML; Valverde ÁM; Mayor F; Murga C
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3655-3667. PubMed ID: 30261289
[TBL] [Abstract][Full Text] [Related]
12. B-cell lymphoma 6 alleviates nonalcoholic fatty liver disease in mice through suppression of fatty acid transporter CD36.
Zhang H; Li Y; Zhang C; Huang K; Zhao J; Le S; Jiang L; Liu H; Yang P; Xiao X; Yu J; Wu J; Ye P; Xia J
Cell Death Dis; 2022 Apr; 13(4):359. PubMed ID: 35436984
[TBL] [Abstract][Full Text] [Related]
13. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.
Miquilena-Colina ME; Lima-Cabello E; Sánchez-Campos S; García-Mediavilla MV; Fernández-Bermejo M; Lozano-Rodríguez T; Vargas-Castrillón J; Buqué X; Ochoa B; Aspichueta P; González-Gallego J; García-Monzón C
Gut; 2011 Oct; 60(10):1394-402. PubMed ID: 21270117
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats.
Li S; Liao X; Meng F; Wang Y; Sun Z; Guo F; Li X; Meng M; Li Y; Sun C
PLoS One; 2014; 9(1):e86724. PubMed ID: 24489777
[TBL] [Abstract][Full Text] [Related]
15. Gracilaria chorda subcritical water ameliorates hepatic lipid accumulation and regulates glucose homeostasis in a hepatic steatosis cell model and obese C57BL/6J mice.
Thakuri LS; Park CM; Kim HA; Kim HJ; Park JW; Park JC; Rhyu DY
J Ethnopharmacol; 2024 Feb; 320():117395. PubMed ID: 37952731
[TBL] [Abstract][Full Text] [Related]
16. Nicotinic acetylcholine receptor α7 subunit improves energy homeostasis and inhibits inflammation in nonalcoholic fatty liver disease.
Li DJ; Liu J; Hua X; Fu H; Huang F; Fei YB; Lu WJ; Shen FM; Wang P
Metabolism; 2018 Feb; 79():52-63. PubMed ID: 29129819
[TBL] [Abstract][Full Text] [Related]
17. Hepatic STAMP2 alleviates high fat diet-induced hepatic steatosis and insulin resistance.
Kim HY; Park SY; Lee MH; Rho JH; Oh YJ; Jung HU; Yoo SH; Jeong NY; Lee HJ; Suh S; Seo SY; Cheong J; Jeong JS; Yoo YH
J Hepatol; 2015 Aug; 63(2):477-85. PubMed ID: 25646886
[TBL] [Abstract][Full Text] [Related]
18. Adipogenic changes of hepatocytes in a high-fat diet-induced fatty liver mice model and non-alcoholic fatty liver disease patients.
Pan X; Wang P; Luo J; Wang Z; Song Y; Ye J; Hou X
Endocrine; 2015 Apr; 48(3):834-47. PubMed ID: 25138963
[TBL] [Abstract][Full Text] [Related]
19. Ascorbic acid inhibits visceral obesity and nonalcoholic fatty liver disease by activating peroxisome proliferator-activated receptor α in high-fat-diet-fed C57BL/6J mice.
Lee H; Ahn J; Shin SS; Yoon M
Int J Obes (Lond); 2019 Aug; 43(8):1620-1630. PubMed ID: 30283077
[TBL] [Abstract][Full Text] [Related]
20. The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight.
Ookawara M; Matsuda K; Watanabe M; Moritoh Y
J Pharmacol Exp Ther; 2020 Oct; 375(1):21-27. PubMed ID: 32719069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
